Anti-Mouse CD279 (PD-1) (Clone RMP1-14) – Purified in vivo PLATINUM™ Functional Grade

Mouse PD-1 transfected BHK cells

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

Clone RMP1-14 recognizes an epitope on mouse PD-1.

PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a co-inhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.

PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells.

PD-L1 (B7-H1), PD-L2

Lymphocyte clonal selection, peripheral tolerance

1.) Ardolino, M. et al. (2018) J Clin Invest. 128(10):4654-4668. PubMed
2.) Schreiber, RD. et al. (2017) Cancer Immunol Res. 5(2):106-117.
3.) Honjo, T. et al. (1992) EMBO J. 11:3887.
4.) Gubin et al. (2018) Cell. 175:1014–1030 Journal Link
5.) Renner et al. (2019) Cell Reports. 29:135–150 Journal Link
6.) Gubin, M. et al. (2018) Cell 175(4):1014-1030.e19 Journal Link